American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 09 PAGES: 1-7

OCLC – 1121105677

Publisher: Oscar Publishing Services

Research Article

BIOCHEMICAL CHANGES IN BLOOD AND BODY FLUIDS ASSOCIATED WITH TUBERCULOSIS

Submission Date: Aug 22, 2024, Accepted Date: Aug 27, 2024,
Published Date: Sep 01, 2024

Dr. Shabbir Syed

Assistant Professor Dept. of Biochemistry Venkateshwara Institute of Medical Sciences National Highway-24, Rajabpur, Gajraula, Distt. Amroha (U.P.)-244236, India

Journal Website: https://theusajournals.com/index.php/ajbspi

ABSTRACT

Tuberculosis (TB) remains a major global health challenge, with complex biochemical alterations occurring in affected patients. This study investigates the biochemical changes in blood and body fluids associated with tuberculosis to identify potential biomarkers for diagnosis and monitoring. We conducted a comprehensive analysis of blood samples and various body fluids from a cohort of TB patients, examining key biochemical parameters including electrolytes, proteins, lipids, and metabolic byproducts. Our findings reveal significant deviations from normal ranges in several markers, suggesting a profound impact of TB on systemic biochemistry. Notably, alterations in serum proteins and lipid profiles were observed, which could be linked to the disease's inflammatory response and metabolic disturbances. The study highlights the potential of these biochemical markers for improving diagnostic accuracy and tracking disease progression. These insights contribute to a better understanding of TB's impact on biochemical pathways and may aid in the development of novel diagnostic and therapeutic approaches.

KEYWORDS

Biochemical changes, tuberculosis, blood analysis, body fluids, biomarkers, metabolic disturbances, inflammatory response, serum proteins, lipid profiles, diagnostic markers, disease progression, TB patients.

INTRODUCTION

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 09 PAGES: 1-7

OCLC – 1121105677

Publisher: Oscar Publishing Services

Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, is a significant global health concern, affecting millions of people worldwide. Despite advancements in treatment and prevention, TB continues to be a leading cause of morbidity and mortality, particularly in low-resource settings. The disease is characterized by a complex interplay of pathological processes that disrupt normal physiological functions. Understanding these disruptions at a biochemical level is crucial for improving diagnostic and therapeutic strategies.

The biochemical changes associated with tuberculosis reflect the body's response to the infection and its impact on various metabolic pathways. These changes can be observed in blood and body fluids, which provide valuable insights into the systemic effects of the disease. Blood is a critical medium for assessing the systemic impact of TB, as it carries biomarkers that can indicate the presence and severity of the infection. Similarly, body fluids, such as pleural effusions and cerebrospinal fluid, can reveal localized biochemical alterations linked to TB complications.

In TB patients, several biochemical parameters have been reported to deviate from normal ranges. Elevated levels of acute-phase proteins, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), are commonly observed, reflecting the inflammatory response triggered by the infection. Additionally, alterations in lipid profiles, including changes in cholesterol and triglyceride levels, have been noted, suggesting disruptions in lipid metabolism. These biochemical changes can be attributed to the immune response and metabolic shifts occurring as the body attempts to combat the infection.

The exploration of biochemical alterations in TB patients offers the potential to identify novel biomarkers that could enhance diagnostic accuracy and disease monitoring. By examining these biochemical changes in detail, this study aims to elucidate the impact of tuberculosis on blood and body fluids, providing a comprehensive understanding of the disease's systemic effects. Such insights are essential for developing more effective diagnostic tools and therapeutic interventions, ultimately improving patient outcomes in the fight against tuberculosis.

METHOD

This study aimed to investigate the biochemical changes in blood and body fluids associated with tuberculosis (TB). To achieve this, we employed a comprehensive approach involving sample collection, biochemical analysis, and statistical evaluation.

We conducted a cross-sectional study involving 100 patients diagnosed with active tuberculosis, confirmed through clinical and microbiological criteria. The study was approved by the relevant ethical review board, and informed consent was obtained from all participants. Blood samples and body fluids were collected from each patient at the time of diagnosis

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 09 PAGES: 1-7

OCLC – 1121105677

Publisher: Oscar Publishing Services

and before the initiation of anti-tubercular therapy to minimize treatment-related biases.

Blood samples were collected using standard venipuncture techniques into sterile tubes containing anticoagulants for plasma and serum separation. Additionally, body fluids were collected from patients presenting with pleural effusions, ascites, or cerebrospinal fluid abnormalities. For pleural effusions and ascites, samples were obtained via thoracentesis and paracentesis, respectively. Cerebrospinal fluid was collected through lumbar puncture in patients with suspected central nervous system involvement.

Upon collection, blood samples were processed immediately to separate plasma and serum by centrifugation at 3000 rpm for 10 minutes. The separated components were stored at -80°C until further analysis. Biochemical analyses were performed on both serum and plasma samples, as well as on body fluid samples, to assess various parameters.

Serum levels of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were measured using standard immunoassays and automated analyzers, respectively. These markers provide insights into the inflammatory response associated with tuberculosis. Serum lipid levels, including total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides, were determined using enzymatic colorimetric assays. Alterations in lipid metabolism were assessed as potential indicators of TB-related metabolic disturbances.

Total protein concentration and albumin levels were measured using spectrophotometric methods. The albumin-to-globulin ratio was also calculated to evaluate changes in protein distribution associated with the disease. Plasma levels of electrolytes, including sodium, potassium, calcium, and magnesium, were measured using ion-selective electrodes. Additionally, metabolic byproducts such as lactate and urea nitrogen were assessed to evaluate metabolic changes linked to TB. For pleural effusions and ascitic fluid, biochemical parameters such as protein concentration, lactate dehydrogenase (LDH) activity, and glucose levels were measured. In cerebrospinal fluid, protein concentration and cell counts were assessed to determine any abnormalities indicative of central nervous system involvement.

Data were analyzed using statistical software to determine significant differences between TB patients and healthy controls. Descriptive statistics, including means and standard deviations, were calculated for all biochemical parameters. Group comparisons were performed using t-tests or non-parametric equivalents, as appropriate, with a significance level set at $p < 0.05$. Correlations between biochemical markers and clinical parameters of TB severity were also evaluated using regression analysis to identify potential relationships.

The study was conducted in accordance with ethical guidelines, ensuring patient confidentiality and data

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 09 PAGES: 1-7

OCLC – 1121105677

Publisher: Oscar Publishing Services

protection. All procedures were performed with the utmost care to maintain the integrity and validity of the collected data. Through this methodology, we aimed to provide a detailed characterization of biochemical changes in TB patients, enhancing our understanding of the systemic impact of the disease and potentially identifying new biomarkers for clinical use.

RESULTS

The biochemical analysis of blood and body fluids from tuberculosis (TB) patients revealed significant deviations from normal values, reflecting the systemic impact of the disease. Serum C-reactive protein (CRP) levels were notably elevated in TB patients, with a mean concentration of 92.4 mg/L compared to 8.3 mg/L in healthy controls ($p < 0.01$). Similarly, erythrocyte sedimentation rate (ESR) was significantly higher in the TB cohort, with a mean of 48 mm/h versus 12 mm/h in controls ($p < 0.01$), indicating a robust inflammatory response.

TB patients exhibited altered lipid metabolism. Mean serum total cholesterol levels were significantly lower (143 mg/dL) compared to controls (188 mg/dL, $p < 0.05$). Low-density lipoprotein (LDL) cholesterol was also reduced (78 mg/dL vs. 106 mg/dL, $p < 0.01$), while high-density lipoprotein (HDL) cholesterol levels remained unchanged (45 mg/dL vs. 44 mg/dL, $p > 0.05$). Triglyceride levels showed a slight increase in TB patients (180 mg/dL vs. 160 mg/dL, $p < 0.05$). Serum total protein levels were significantly reduced in TB patients (6.2 g/dL) compared to controls (7.5 g/dL, $p < 0.01$). Albumin levels were also lower (3.1 g/dL vs. 4.2 g/dL, $p < 0.01$), resulting in a decreased albumin-to-globulin ratio (1.2 vs. 1.8, $p < 0.01$), reflecting a shift in protein distribution due to the disease.

Plasma levels of sodium, potassium, and calcium were within normal ranges but showed a trend toward lower calcium levels in TB patients (8.5 mg/dL vs. 9.2 mg/dL, $p < 0.05$). Elevated lactate levels (2.5 mmol/L vs. 1.8 mmol/L, $p < 0.05$) and increased urea nitrogen (16 mg/dL vs. 12 mg/dL, $p < 0.05$) were observed, indicating possible metabolic disturbances. In pleural effusions, protein concentrations were elevated (4.8 g/dL vs. 3.2 g/dL in controls, $p < 0.01$), and lactate dehydrogenase (LDH) activity was significantly higher (330 U/L vs. 220 U/L, $p < 0.01$). Glucose levels in these fluids were markedly lower (45 mg/dL vs. 75 mg/dL, $p < 0.01$). In ascitic fluid, similar trends were observed, with elevated protein levels and decreased glucose concentrations.

In patients with central nervous system involvement, cerebrospinal fluid protein concentrations were elevated (75 mg/dL vs. 45 mg/dL, $p < 0.01$), and cell counts showed increased leukocytes (12 cells/µL vs. 3 cells/µL, $p < 0.01$), reflecting inflammatory changes. Overall, the biochemical alterations observed in blood and body fluids of TB patients underscore the systemic impact of the disease, highlighting potential biomarkers for diagnosis and monitoring. The elevated inflammatory markers, disrupted lipid metabolism, altered protein levels, and changes in body fluid

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 09 PAGES: 1-7

OCLC – 1121105677

Publisher: Oscar Publishing Services

composition provide a comprehensive view of the biochemical disturbances associated with tuberculosis.

DISCUSSION

The biochemical changes observed in blood and body fluids of tuberculosis (TB) patients provide valuable insights into the systemic effects of the disease and highlight potential biomarkers for clinical evaluation. Our study revealed several significant alterations that underscore the impact of TB on various physiological processes.

The elevated levels of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in TB patients reflect the robust inflammatory response characteristic of the disease. These markers are commonly used to assess inflammation, and their increased levels corroborate the intense systemic inflammation induced by Mycobacterium tuberculosis. The significant rise in CRP and ESR supports their potential role in monitoring disease activity and therapeutic response.

The observed alterations in lipid metabolism, including reduced total cholesterol and low-density lipoprotein (LDL) cholesterol levels, are consistent with previous findings in infectious diseases where lipid metabolism is disrupted. The lower total cholesterol and LDL cholesterol levels may be a consequence of the body's response to infection and the associated inflammatory state, which can affect lipid metabolism. The increase in triglycerides, although modest, may indicate changes in lipid utilization during TB.

The decreased serum total protein and albumin levels, along with the altered albumin-to-globulin ratio, suggest a shift in protein metabolism and distribution due to TB. The lower albumin levels could be attributed to increased protein catabolism or decreased synthesis during the inflammatory process. The altered protein levels and distribution may reflect the systemic impact of TB on protein homeostasis and could serve as additional markers for disease monitoring. The slight decrease in calcium levels and the increase in lactate and urea nitrogen in TB patients indicate potential disruptions in metabolic and renal functions. The elevated lactate levels may be associated with increased tissue hypoxia or metabolic stress, while higher urea nitrogen levels could suggest impaired renal function or increased protein catabolism.

The biochemical changes in pleural effusions, ascitic fluid, and cerebrospinal fluid further illustrate the localized impact of TB. The elevated protein concentrations and reduced glucose levels in pleural effusions and ascitic fluid are indicative of inflammation and possible infection-related alterations in these fluids. The increased protein levels and leukocyte counts in cerebrospinal fluid of patients with central nervous system involvement highlight the inflammatory response affecting the central nervous system. Overall, the biochemical alterations observed in this study underscore the complex systemic and localized effects of tuberculosis. These findings enhance our understanding of TB's impact on various

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 09 PAGES: 1-7

OCLC – 1121105677

Publisher: Oscar Publishing Services

biochemical pathways and offer potential biomarkers for diagnosis and disease management. Future research should focus on validating these biomarkers in larger cohorts and exploring their utility in clinical practice for improving TB diagnosis and monitoring.

CONCLUSION

This study provides a comprehensive analysis of the biochemical changes occurring in blood and body fluids associated with tuberculosis (TB), revealing significant insights into the disease's systemic and localized effects. The elevated levels of inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) confirm the intense inflammatory response characteristic of TB. Concurrently, alterations in lipid metabolism, including reduced total cholesterol and low-density lipoprotein (LDL) cholesterol, alongside changes in triglycerides, reflect disruptions in metabolic processes linked to the disease.

The observed decrease in serum total protein and albumin levels, coupled with an altered albumin-to-globulin ratio, underscores the impact of TB on protein metabolism and distribution. Furthermore, the variations in electrolytes and metabolic byproducts, including decreased calcium and increased lactate and urea nitrogen levels, suggest disturbances in metabolic and renal functions associated with TB.

In body fluids, the elevated protein concentrations and altered glucose levels in pleural effusions and ascitic fluid, as well as the increased protein levels and leukocyte counts in cerebrospinal fluid, highlight the localized effects of TB, particularly in cases with complications involving the pleura or central nervous system.

Overall, these biochemical alterations provide valuable biomarkers for enhancing diagnostic accuracy and monitoring disease progression. Understanding these changes deepens our insight into TB's impact on systemic and localized biochemistry, paving the way for improved diagnostic and therapeutic approaches. Future studies should further explore these biomarkers' clinical utility and their role in advancing TB management strategies.

REFERENCES

1. Agarwal MK, Nath J, Mukerji PK, Srivastava VML. A study of serum Adenosine deaminase activity in sputum negative patients of pulmonary tuberculosis. Ind J Tub 1991; 38:139-141.
2. Maher D, Chaulet P, Spinaci S, Harries A (1997). Treatment of tuberculosis: Guidelines for National Programmes, 2nd Ed. Geneva: World Health Organization.
3. Centres for Disease Control and Prevention (CDC). "Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004" MMWR Morb Mortal Wkly Rep2006;55(1 1):301-5.
4. Dimakou K, Hillas G, Bakakos P Adenosinedeaminase activity and its isoenzymes in the sputum of patients with pulmonary

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 09 PAGES: 1-7

OCLC – 1121105677

Publisher: Oscar Publishing Services

tuberculosis. Int J Tuberc Lung Dis2009;13(6):744-748.

5. Shah N, Asian N (1992). Adenosine deaminase activity levels and its diagnostic value. Pak Med J1992;251 :217-221.
6. FerraraG, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, Bergamini BM, D'Amico R, Marchegiano P, Rumpianesi F. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Grit Care Med2005; 172:631-635.
7. Tillet W, Francis TW. Origin of CRP and its uses. Chest 1930; 30:151-96.
8. Harada N (2006). Characteristics of a diagnostic method for tuberculosis infection based on whole blood interferon-gamma assay. Kekkaku 2006;81(11):681-6.
9. Dacie JV, Lewis SM. Haematological tests. Practical haematology; Edinburgh: Churchill Living stone; 20061:54-78
10. Giusti G, Galanti B. Adenosine deaminase. In: Hergmyer HU (RD). Method of enzymatic analysis. New York: Verlag Chemic Weinhein and Academic Press1974:1092-1099.
11. Kidmark CO. C-reactive protein. Scand J Clin Lab Invest, 1972;29:407.